Debate: anti-CD38-VRd quads versus anti-CD38-KRd quads in newly diagnosed myeloma

Mechanisms of action of CD38 antibodies in myelomaПодробнее

Comparing the thromboembolic risk with KRd versus VRd in newly diagnosed myelomaПодробнее

Stem cell collection in patients with multiple myeloma treated with anti-CD38 monoclonal antibodiesПодробнее

A retrospective study analyzing outcomes of patients with anti-CD38 refractory myelomaПодробнее

What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple MyelomaПодробнее

KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple MyelomaПодробнее

What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple MyelomaПодробнее

The impact of the addition of anti-CD38 monoclonal antibodies to the frontline treatment of myelomaПодробнее

Mechanistic insights into the resistance to anti-CD38 therapyПодробнее

Anti-CD38 immunotherapy treatment for multiple myelomaПодробнее

The management of patients with myeloma who are anti-CD38 refractoryПодробнее

Anti-CD38 monoclonal antibodies – a new drug class for treating myelomaПодробнее

The importance of anti-CD38 monoclonal antibodies for multiple myelomaПодробнее

Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAbПодробнее

Triplet vs quadruplet regimens for NDMM: selecting between these optionsПодробнее

Dr. Noopur Raje Discusses Anti-CD38 Antibodies in MyelomaПодробнее

Is re-treatment possible with anti-CD38 therapies?Подробнее

Efficacy of Teclistimab versus current treatments in patients with triple-class exposed RR myelomaПодробнее

CD38-targeting triplets for myelomaПодробнее